On April 28, 2020 Immunovia reported that first quarter interim report for January – March 2020 (Press release, Immunovia, APR 28, 2020, View Source;march-2020-301048485.html [SID1234556721]). It is available on Immunovia’s website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"During Q1 2020, Immunovia worked hard and continued to make great strides towards IMMray PanCan-d’s launch and the sales start of the first test for early diagnosis of pancreatic cancer, in spite of the COVID-19 global pandemic.
Work on the verification study proceeded as planned and we received all the blood samples from our KOL network. In January, our commercial team prepared detailed plans for the launch and in March and April these plans were adapted significantly to accommodate the COVID-19 situation. This included making in-person activities, such as conferences and the patient organization meetings that were canceled, into digital activities, etc.
In January, Immunovia welcomed a new Senior VP Sales NA (North America), Michael Pettigrew, to the team. Michael brings with him a very successful track record in product launches and sales growth in life science, along with unique leadership qualities. He is an important addition to Immunovia.
Following the end of Q1 2020, we provided an update on the measures the company has taken and continues to take in order to support patients, employees and public health initiatives in response to the COVID-19 pandemic. We also announced other crucial preparations that Immunovia has made in response to COVID-19, such as securing inventories of critical consumables, the successful collection of samples for the verification study including the reallocation of extra blood samples to the efforts of securing all samples for the verification study. All this done to facilitate the uninterrupted continuation towards commercialization start.
We reiterate that Immunovia’s R&D laboratories and clinical laboratory in Lund, along with the production facilities are fully operational. They all have plans in place to help sustain operations in these unusual times."
– Excerpt from the CEO Mats Grahn’s comment on the report
First Quarter Interim Report for January – March 2020 Call Details:
Immunovia invites to a teleconference (in English) for investors, analysts and media on Tuesday, April 28th, 2020 at 16:30 CET.
Mats Grahn, CEO will present Immunovia and comment on the first quarter interim report for the period January – March 2020 followed by a Q&A session.
There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (View Source) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET on April 28, 2020.